Compare Franklin Resources, Inc. (BEN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franklin Resources, Inc. vs Sana Biotechnology Inc — how do they compare? Franklin Resources, Inc. trades at $33.37 (market cap $16.95B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Franklin Resources, Inc. is far larger — about 15× Sana Biotechnology Inc's market cap, and Franklin Resources, Inc. pays a 3.96% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| BEN | SANA | |
|---|---|---|
Market Cap | $16.95B | $1.13B |
Sector | Financials | Health |
52-Week High | $35.77 | $5.92 |
52-Week Low | $21.18 | $2.68 |
Enterprise Value | $29.90B | $1.05B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franklin Resources (BEN) trades at $33.59, up 0.21% on the day, with a bullish technical signal and consistent earnings beats. The company reported record AUM of $1.80 trillion as of July 31, 2026 (Business Wire, 2026-08-05), driven by strong inflows and diversification. Fundamentals show revenue growth to $8.77B in 2025 and a net income margin of 5.98%, though ROE remains low at 1.34%.
The outlook is positive with a consensus price target of $36.50 (22 analysts, August 2026) and recent momentum from private markets expansion. Key risks include volatile cash flows, with a net cash outflow of $835M in 2025, and competitive fee pressures. The stock offers upside potential but requires monitoring of margin sustainability and market-sensitive AUM growth.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
